Why BioNTech Stock Tumbled on Tuesday
_0.png?locale=de){kind=logo}
For the second straight day, the share price of otherwise popular coronavirus stock BioNTech (NASDAQ: BNTX) fell on Tuesday. Despite there being no direct catalysts for such a drop, the shares of the German company ended the day nearly 3.5% lower.
BioNTech is, it nearly goes without saying by now, the co-developer of the Comirnaty coronavirus vaccine with pharmacuetical sector powerhouse Pfizer (NYSE: PFE). The jab is the only one fully approved for use in the U.S.; vaccines from Moderna and Johnson & Johnson's Janssen currently hold only Emergency Use Authorization (EUA).
Image source: Getty Images.
Source Fool.com
